期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

应用蛋白质组学技术筛选胰腺癌生物标志物的研究进展

Research progress in screening biomarkers of pancreatic cancer by proteomic techniques
下载PDF
导出
摘要 胰腺癌是一种十分凶险的恶性肿瘤.胰腺癌早期症状不明显,临床确诊的患者多已处于中晚期,大多失去手术治疗机会.蛋白质组技术的快速发展为研究胰腺癌发病机制、发现早期诊断和预后的生物标志物提供了可能.本文就蛋白质组学技术在胰腺癌细胞系、组织、血清和胰液等方面的应用作一综述. Pancreatic cancer is one kind of devastating diseases. Those patients without nonspecific symptoms at early stage had mostly lost the opporunity of surgical therapy when pancreatic cancer was detected at advanced stage. Rapid growth of proteornic technologies provides possibilities to study etiopathogenesis, and screen early diagnostic and prognosis biomarkers of pancreatic cancer. In this paper, the application of proteomic techniques in cell lines, tissues, serum and pancreatic juice from patients with pancreatic cancer is reviewed briefly.
作者 刘辉 张海婧 陈国强 吕丽艳 李智立
机构地区 中国医学科学院中国协和医科大学基础医学研究所
出处 《世界华人消化杂志》 CAS 北大核心 2007年第14期1628-1633,共6页 World Chinese Journal of Digestology
基金 北京市自然科学基金 No.7062042~~
关键词 蛋白质组学 胰腺癌 双向凝胶电泳 质谱 电喷雾电离 基质辅助激光解析电离 Proteomics Pancreatic cancer Twodimensional polyacrylamide gel electrophoresis Mass spectrometry Electrospray ionization Matrixassisted laser desorption/ionization
分类号 R735.9 [医药卫生—肿瘤]
  • 相关文献

参考文献64

  • 1Neoptolemos JP,Dunn JA,Stocken DD,Almond J,Link K,Beger H,Bassi C,Falconi M,Pederzoli P,Dervenis C,Fernandez-Cruz L,Lacaine F,Pap A,Spooner D,Kerr DJ,Friess H,Buchler MW.Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer:a randomised controlled trial.Lancet 2001; 358:1576-1585
  • 2Guo X,Cui Z.Current diagnosis and treatment of pancreatic cancer in China.Pancreas 2005; 31:13-22
  • 3Chang CY,Huang SP,Chiu HM,Lee YC,Chen MF,Lin JT.Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan.Hepatogastroenterology 2006;53:1-4
  • 4Lowe D,Lee J,Schade R,Chaudhary A.Patient with markedly elevated CA 19-9 not associated with malignancy.South Med J 2006; 99:306-308
  • 5Kilic M,Gocmen E,Tez M,Ertan T,Keskek M,Koc M.Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer.Can J Surg 2006; 49:241-244
  • 6Marchese R,Muleti A,Pasqualetti P,Bucci B,Stigliano A,Brunetti E,De Angelis M,Sazzoni G,Tocchi A,Brozzetti S.Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA.Pancreas 2006; 32:171-177
  • 7Campman SC,Fajardo MA,Rippon MB,Kraegel SA,Ruebner BH.Adenosquamous carcinoma arising in a mucinous cystadenoma of the pancreas.J Surg Oncol 1997; 64:159-162
  • 8Wu X,Lu XH,Xu T,Qian JM,Zhao P,Guo XZ,Yang XO,Jiang WJ.Evaluation of the diagnostic value of serum tumor markers,and fecal k-ras and p53 gene mutations for pancreatic cancer.Chin J Dig Dis 2006; 7:170-174
  • 9Gerdes B,Ramaswamy A,Ziegler A,Lang SA,Kersting M,Baumann R,Wild A,Moll R,Rothmund M,Bartsch DK.p16INK4a is a prognostic marker in resected ductal pancreatic cancer:an analysis of p16INK4a,p53,MDM2,an Rb.Ann Surg 2002; 235:51-59
  • 10Kawahira H,Kobayashi S,Kaneko K,Asano T,Ochiai T.p53 protein expression in intraductal papillary mucinous tumors (IPMT) of the pancreas as an indicator of tumor malignancy.Hepatogastroenterology 2000; 47:973-977
世界华人消化杂志
2007年 第14期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部